Nihon Kohden Q4 2025 Earnings Report

Nihon Kohden EPS Results

• Actual EPS: $0.18
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Nihon Kohden Revenue Results

• Actual Revenue: $439.11 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Nihon Kohden Announcement Details

• Quarter: Q4 2025
• Date: 5/13/2025
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Nihon Kohden (OTCMKTS:NHNKY) is a Tokyo-based manufacturer of medical electronic equipment, founded in 1951. The company has built a reputation for innovation in patient monitoring and diagnostic systems, developing one of Japan’s earliest electrocardiogram (ECG) machines and pioneering transistor-based oscilloscopes for clinical use. Over the decades, Nihon Kohden has expanded its product portfolio to address a wide range of healthcare needs, from emergency response to intensive care and neurology.

The company’s core offerings include patient monitors, ECG and electroencephalograph (EEG) devices, defibrillators, infusion pumps, and neuromonitoring systems. Its patient monitoring solutions provide real-time data on vital signs such as heart rate, blood pressure and oxygen saturation, while its EEG and electromyography (EMG) instruments support neurological diagnosis and research. Nihon Kohden also supplies comprehensive alarm management and clinical information systems designed to integrate data across hospital departments, helping clinicians make timely, informed decisions.

Nihon Kohden serves healthcare providers globally, with sales and distribution networks spanning Japan, North America, Europe and Asia-Pacific. The company maintains manufacturing and research facilities in Japan and overseas, collaborating with hospitals and academic institutions to advance medical technologies. Through ongoing investment in research and development, Nihon Kohden continues to focus on enhancing the accuracy, connectivity and usability of its devices to support patient safety and clinical efficiency.